Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

• Published in: Scientific reports 2018-09, Vol.8 (1), p.14458-7, Article 14458
• Main Authors: Zhao, Yannan, Liu, Cheng, Zhang, Yingjian, Gong, Chengcheng, Li, Yi, Xie, Yizhao, Wu, Bingrui, Yang, Zhongyi, Wang, Biyun
• Format: Article
• Language: English
• Subjects: 692/4028/67/1347; 692/4028/67/2329; Breast cancer; Coefficient of variation; Computed tomography; Drug resistance; ErbB-2 protein; Estrogens; Fulvestrant; Glycolysis; Heterogeneity; Heterogeneity Parameter; Humanities and Social Sciences; Intra-tumor Heterogeneity; Liver; Medical prognosis; Metabolic Tumor Volume; Metastases; Metastasis; Metastatic Breast Cancer Patients; multidisciplinary; Multivariate analysis; Patients; Positron emission tomography; Science; Science (multidisciplinary); Statistical analysis; Survival; Total Lesion Glycolysis (TLG); Tumors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-32745-z

Heterogeneity has been demonstrated to be a predictor of treatment failure and drug resistance. Our study aimed to investigate imaging parameters, including tumor heterogeneity, as prognostic factors of response to 500 mg fulvestrant using 18F-FDG PET/CT. Twenty-seven estrogen receptor (HR)-positive/HER2-negative metastatic breast cancer patients who received 500 mg fulvestrant and underwent 18F-FDG PET/CT before treatment were retrospectively included. In PET/CT scans, conventional parameters (maximum and mean standardized uptake value, metabolic tumor volume [MTV], total lesion glycolysis [TLG]) and heterogeneity parameters (intra-tumor heterogeneity index [HI] and inter-tumor heterogeneity coefficient of variation [COV]) were analyzed. Progression-free survival (PFS) was mainly assessed for efficacy. The survival analyses were performed using the Kaplan–Meier method. Univariate and multivariate analysis were performed using the Cox proportional hazard model. Univariate analysis indicated that a high SUVmax and a high tumor HI at baseline were associated with longer PFS of fulvestrant (P = 0.036 and P = 0.033, respectively). Liver metastasis, SUVmax and HI were statistically significant in multivariate analysis (P values of 0.017, 0.025 and 0.043, respectively). 18F-FDG based intra-tumor heterogeneity appears to be a potential predicator of efficacy of fulvestrant among HR+HER2− metastatic breast cancer patients.